Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | PAK4 | O96013 | 7/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | ULK1 | O75385 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.33 |
| ▸ | ERCC2 | P18074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17878698 | 0.86 | NR1H2 (0.37) | CDK2CCNA2CCNA1NR1H2C5AR1 | |
| SCHEMBL16627099 | 0.85 | CDK2 (0.43) | CDK2CCNA2CCNA1NR1H2GSK3B | |
| SCHEMBL597015 | 0.80 | CDK2 (0.40) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL19195046 | 0.76 | NR1H2 (0.38) | CDK2CCNA2CCNA1NR1H2GSK3B | |
| SCHEMBL26407436 | 0.76 | NR1H2 (0.35) | CDK2CCNA2CCNA1NR1H2C5AR1 | |
| SCHEMBL22095959 | 0.75 | C5AR1 (0.39) | CDK2CCNA2CCNA1NR1H2GSK3B | |
| SCHEMBL1837535 | 0.75 | NR1H2 (0.36) | CDK2CCNA2CCNA1NR1H2GSK3B | |
| SCHEMBL6375680 | 0.74 | C5AR1 (0.35) | CDK2CCNA2CCNA1NR1H2C5AR1 | |
| SCHEMBL7947109 | 0.72 | NR1H2 (0.36) | CDK2CCNA2CCNA1NR1H2C5AR1 | |
| SCHEMBL19200586 | 0.72 | C5AR1 (0.41) | NR1H2C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12491251-B2 | Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-3236959-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4010336-B1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2025-04-02 | — | — | EP | disclosed |
| CN-114174281-B | Degradation agent for cyclin-dependent kinase 7 (CDK 7) and use thereof | 达纳-法伯癌症研究公司 | 2025-02-07 | — | — | CN | disclosed |
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | PFIZER ITALIA S.R.L. (IT) | 2009-09-03 | — | — | US | disclosed |
| US-7563787-B2 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-7531531-B2 | Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-05-12 | — | — | US | disclosed |
| WO-2008096260-A1 | 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS | PFIZER INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-08-16 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PRKCB, PRKCA, PRKCQ | CDK2 10/4885CCNA2 534/4885CCNA1 478/4885 |
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 7/4885CCNA2 41/4885CCNA1 32/4885 |
| US-20070142368-A1 | Substituted pyrazole compounds | AURKC, AURKA, AURKB | CDK2 11/4885CCNA2 267/4885CCNA1 694/4885 |
| US-12491251-B2 | Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof | CDK7, CDK8, CDK17 | CDK2 8/4885CCNA2 30/4885CCNA1 42/4885 |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | AURKC, AURKA, AURKB | CDK2 26/4885CCNA2 333/4885CCNA1 940/4885 |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CDK2, CDK5, CDK9 | CDK2 1/4885CCNA2 14/4885CCNA1 36/4885 |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | CDK2 43/4885CCNA2 848/4885CCNA1 793/4885 |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | MAP3K20, PLK2, PRKAA1 | CDK2 70/4885CCNA2 1043/4885CCNA1 1090/4885 |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | CDK2 43/4885CCNA2 848/4885CCNA1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.